Patents Assigned to Kagoshima University
  • Publication number: 20210008134
    Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
    Type: Application
    Filed: November 8, 2018
    Publication date: January 14, 2021
    Applicant: KAGOSHIMA UNIVERSITY
    Inventors: Ken-ichiro KOSAI, Nobuhiro IJICHI
  • Patent number: 10882005
    Abstract: A hydrogen gas producing apparatus includes a porous body (100) and a mixed gas source (300). The porous body (100) is permeable to hydrogen gas and carbon dioxide gas, and has a property of being more permeable to hydrogen gas than carbon dioxide gas. The mixed gas source (300) causes a mixed gas including carbon dioxide gas and hydrogen gas to flow into the porous body (100) under a condition that a pressure gradient represented by (P1?P2)/L is below 50 MPa/m, where L represents the length of the porous body (100) in a direction in which the mixed gas permeates; P1 represents an inflow pressure of the mixed gas into the porous body (100); and P2 represents an outflow pressure thereof from the porous body (100).
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: January 5, 2021
    Assignee: Kagoshima University
    Inventors: Yoshihiro Hirata, Taro Shimonosono, Hikari Imada
  • Patent number: 10772887
    Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Kagoshima University
    Inventors: Daisuke Kodama, Shuji Izumo
  • Patent number: 10738324
    Abstract: Disclosed is a vector, preferably a viral vector, containing a treatment factor and/or a nucleic acid encoding a cytotoxic factor under control of an Aurora kinase promoter. Also disclosed is a virus vector in which the promoter of a nucleic acid encoding a factor necessary to the replication or assembly of at least one virus is substituted by the Aurora kinase promoter. Also disclosed are a disease treatment agent, in particular a cancer treatment agent, which contains the aforementioned vector, and a clinical diagnostic agent, in particular a cancer diagnostic agent, which contains the vector containing the Aurora kinase promoter.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: August 11, 2020
    Assignee: KAGOSHIMA UNIVERSITY
    Inventor: Ken-ichiro Kosai
  • Publication number: 20200181196
    Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.
    Type: Application
    Filed: June 12, 2017
    Publication date: June 11, 2020
    Applicant: Kagoshima University
    Inventors: Yuji ITO, Yoshinari SHOYAMA, Akio HAYASHI, Norihito NAKATA
  • Publication number: 20200171454
    Abstract: An object of the invention is to provide a method for producing a capsule or microbead having high encapsulation efficiency of an encapsulated substance, high production efficiency, and high versatility. The invention relates to a method for producing a microcapsule or microbead, comprising: a step of disposing a monomer droplet or polymer droplet containing a substance to be encapsulated, which has a surface coated with a plurality of solid fine particles, on a flat surface; and a step of solidifying the monomer droplet or polymer droplet disposed on the flat surface in a gas phase so as to form an outer shell of a capsule or microbead, thereby forming a region enclosed by the outer shell, wherein the substance is encapsulated in the region.
    Type: Application
    Filed: August 8, 2018
    Publication date: June 4, 2020
    Applicant: KAGOSHIMA UNIVERSITY
    Inventors: Takayuki TAKEI, Masahiro YOSHIDA, Yoshihiro OHZUNO, Gen HAYASE
  • Patent number: 10662441
    Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: May 26, 2020
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Kenichiro Kosai, Yuqing Wang
  • Patent number: 10627412
    Abstract: The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: April 21, 2020
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Ikuro Maruyama, Teruto Hashiguchi, Salunya Tancharoen, Ko-ichi Kawahara, Kenji Tanaka, Lyang-ja Lee
  • Patent number: 10517928
    Abstract: According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: December 31, 2019
    Assignee: Kagoshima University
    Inventors: Akio Ido, Hirohito Tsubouchi, Yuga Komaki
  • Publication number: 20190389803
    Abstract: The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 26, 2019
    Applicants: Kagoshima University, Nobelpharma Co., Ltd.
    Inventors: Masanori BABA, Masaaki TOYAMA, Norikazu SAKAKIBARA
  • Patent number: 10508709
    Abstract: In a vibration damping device 20, the moment of inertia J1 of a driven member 15, the moment of inertia J2 of an inertial mass body 23, the mass m of crank members 22, the distance L3 between the center of gravity G of the crank member 22 and the fulcrum of swinging of the crank member 22 with respect to the inertial mass body 23, and the distance L4 between this fulcrum and the center of rotation RC are determined so that torque fluctuation of an object for which vibration is to be damped, which is derived based on angular displacement and angles obtained by solving an equation of motion for the driven member 15 and an equation of motion for the entire vibration damping device 20 is equal to a target value.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 17, 2019
    Assignees: AISIN AW CO., LTD., NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY, Kagoshima University
    Inventors: Yoichi Oi, Masaki Wajima, Hiroki Nagai, Takao Sakamoto, Takahiro Ryu, Takashi Nakae, Kenichiro Matsuzaki
  • Publication number: 20190367560
    Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicants: Kagoshima University, Daicel Corporation
    Inventors: Yuji Ito, Seiichi Uchimura
  • Publication number: 20190352397
    Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
    Type: Application
    Filed: December 25, 2017
    Publication date: November 21, 2019
    Applicants: Kyowa Hakko Kirin Co., Ltd., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki TAKAHASHI, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO
  • Publication number: 20190226552
    Abstract: In a vibration damping device 20, the moment of inertia J1 of a driven member 15, the moment of inertia J2 of an inertial mass body 23, the mass m of crank members 22, the distance L3 between the center of gravity G of the crank member 22 and the fulcrum of swinging of the crank member 22 with respect to the inertial mass body 23, and the distance L4 between this fulcrum and the center of rotation RC are determined so that torque fluctuation of an object for which vibration is to be damped, which is derived based on angular displacement and angles obtained by solving an equation of motion for the driven member 15 and an equation of motion for the entire vibration damping device 20 is equal to a target value.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Applicants: AISIN AW CO., LTD., NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY, Kagoshima University
    Inventors: Yoichi OI, Masaki WAJIMA, Hiroki NAGAI, Takao SAKAMOTO, Takahiro RYU, Takashi NAKAE, Kenichiro MATSUZAKI
  • Publication number: 20190160067
    Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.
    Type: Application
    Filed: August 2, 2017
    Publication date: May 30, 2019
    Applicant: Kagoshima University
    Inventors: Daisuke KODAMA, Shuji IZUMO
  • Publication number: 20190111103
    Abstract: A peptide or a salt thereof having an amino acid sequence represented by (a) or (b) shown below having a promotive effect on a proliferation of fibroblast cells, a composition for enhancing proliferation of fibroblast cells containing one or more of them, a composition for enhancing elastin production in fibroblast cells containing one or more peptides or salts thereof having an amino acid sequence represented by (a), (b) or (c) shown below and a composition for enhancing elastin production in chondrocytes containing one or more peptides or salts thereof having an amino acid sequence represented by (c) shown below.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 18, 2019
    Applicants: Hayashikane Sangyo Co., Ltd., Kagoshima University
    Inventors: Eri Shiratsuchi, Kenji Miyanari, Kazunari Arima, Taihei Yamaguchi, Takahito Komine, Mizuki Takuno
  • Patent number: 10263634
    Abstract: AD conversion is performed by using a combination of a parallel AD converter that includes a plurality of comparators to compare an input potential of an analog input signal sampled by a track and hold circuit and reference potentials different from one another and determines a value of a predetermined number of bits on the higher-order side of a digital signal and a single-slope AD converter that reduces the input potential of the analog input signal sampled by the track and hold circuit at a constant speed, converts a time taken until the reduced input potential becomes equal to a reference potential corresponding to the value determined by the parallel AD converter to a digital value, and determines a remaining value on the lower-order side of the digital signal, and thereby the number of bits of the single-slope AD converter can be reduced and high-speed AD conversion is enabled with a small area and low power consumption.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: April 16, 2019
    Assignee: KAGOSHIMA UNIVERSITY
    Inventor: Kenichi Ohhata
  • Patent number: 10227383
    Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 12, 2019
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Publication number: 20190070207
    Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).
    Type: Application
    Filed: March 10, 2017
    Publication date: March 7, 2019
    Applicants: KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, DAIKIN INDUSTRIES, LTD.
    Inventors: Masanori IKEDA, Midori TAKEDA, Masanori BABA, Nobuyuki KATO
  • Patent number: D884181
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 12, 2020
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Tomonori Iwasaki, Youichi Yamasaki